Jeff Yass’s CytoMed Therapeutics GDTC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$26.5K Buy
+31,399
New +$28.8K ﹤0.01% 13063
2026
Q1
– Sell
-29,829
Closed -$39.7K – 13488
2025
Q4
$39.7K Buy
+29,829
New +$57.8K ﹤0.01% 11825

Other funds holding GDTC

Jeff Yass's GDTC Position: Q3 2026 in Review

Jeff Yass opened a new position in CytoMed Therapeutics (GDTC) in Q3 2026: 31,399 shares worth $26.5K. The stake represents ﹤0.01% of the portfolio and ranks #13063 among its holdings. This is a return to the name: Jeff Yass previously reported a position in GDTC as recently as Q4 2025.

Jeff Yass first reported a position in GDTC in Q4 2025 and has held it in 2 quarters since. The position peaked at $39.7K in Q4 2025. 6 funds tracked by Wall St. Rank hold GDTC as of Q3 2026.

  • Jeff Yass held 31,399 shares of CytoMed Therapeutics worth $26.5K as of Q3 2026.
  • CytoMed Therapeutics was a new Jeff Yass position in Q3 2026.
  • CytoMed Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #13063 holding.
  • Jeff Yass first reported a position in CytoMed Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Jeff Yass's CytoMed Therapeutics position peaked at $39.7K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held CytoMed Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.